- Home
- REGCP vs GNLX Comparison
REGCP vs GNLX Comparison
Compare REGCP & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGCP
- GNLX
- Stock Information
- Founded
- REGCP N/A
- GNLX 2001
- Country
- REGCP United States
- GNLX United States
- Employees
- REGCP 497
- GNLX N/A
- Industry
- REGCP
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- REGCP
- GNLX Health Care
- Exchange
- REGCP Nasdaq
- GNLX Nasdaq
- Market Cap
- REGCP N/A
- GNLX 103.6M
- IPO Year
- REGCP N/A
- GNLX 2023
- Fundamental
- Price
- REGCP $23.61
- GNLX $2.27
- Analyst Decision
- REGCP
- GNLX Strong Buy
- Analyst Count
- REGCP 0
- GNLX 4
- Target Price
- REGCP N/A
- GNLX $18.25
- AVG Volume (30 Days)
- REGCP N/A
- GNLX 141.5K
- Earning Date
- REGCP N/A
- GNLX 11-14-2024
- Dividend Yield
- REGCP N/A
- GNLX N/A
- EPS Growth
- REGCP N/A
- GNLX N/A
- EPS
- REGCP N/A
- GNLX N/A
- Revenue
- REGCP N/A
- GNLX $8,000.00
- Revenue This Year
- REGCP N/A
- GNLX N/A
- Revenue Next Year
- REGCP N/A
- GNLX N/A
- P/E Ratio
- REGCP N/A
- GNLX N/A
- Revenue Growth
- REGCP N/A
- GNLX N/A
- 52 Week Low
- REGCP N/A
- GNLX $1.60
- 52 Week High
- REGCP N/A
- GNLX $16.60
- Technical
- Relative Strength Index (RSI)
- REGCP 36.71
- GNLX 38.68
- Support Level
- REGCP $23.34
- GNLX $2.13
- Resistance Level
- REGCP $23.60
- GNLX $2.80
- Average True Range (ATR)
- REGCP 0.25
- GNLX 0.20
- MACD
- REGCP -0.05
- GNLX -0.04
- Stochastic Oscillator
- REGCP 28.18
- GNLX 14.21
About REGCP Regency Centers Corporation
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.